(Uhmm.. no, not what you think...)
AstraZeneca is a British-Swedish multinational pharmaceutical and biopharmaceutical company headquartered at Cambridge, UK, whereas Aurobindo Pharma Limited is an Indian pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients.
AstraZeneca holds patent for the – Daliresp (trade name for Roflumilast). Daliresp is administered to curb inflammatory condition of the lungs.
Recently, AstraZeneca filed a petition at the US District Court of New Jersey, alleging that Aurobindo intends to launch a generic version of the Daliresp drug which is likely to violate their patent rights on 3 counts. The generic version of the drug though has been approved by the FDA maybe prevent them from being available in the market due to plausible patent infringements.
AstraZeneca in its case prayed for a permanent injunction, restraining and directing Aurobindo Pharma from indulging in making, using, selling, offering to sell, or importing any such product that infringes the patent rights of the company.
Compiled by: Adv. Sachi Kapoor | Concept & Edited by: Dr. Mohan Dewan
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
